Allergan settles patent dispute with Amneal
Dublin-based pharmaceutical company Allergan has revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.
The settlement, announced yesterday, centred on patent infringement litigation brought by Forest and Adamas when Amneal applied for an Abbreviated New Drug Application (ANDA).
Amneal,a manufacturer (of unbranded prescription products, had tried to seek approval to market generic versions of Allergan’s Namzaric (memantine and donepezil hydrochlorides).
Under the terms of the settlement agreement, Forest and Adamas will grant Amneal a license to market generic versions of Namzaric from January 1, 2025. The settlement is subject to review by the US Federal Trade Commission. Alternatively, Amneal may have theoption to launch an authorised generic version of Namzaric from January 1, 2026.
Allergan, Forest and Adamas have also brought patent infringement litigation against Amerigan Pharmaceuticals.
Amerigan has filed an ANDA seeking approval to market generic versions of Namzaric. This suitis pending in the US District Court for the District of Delaware.
